AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2378237 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective blanket
Number of subjects: 40
Study 2378237 — intervention group
Group type: COMPARATOR
Intervention: Warmed cotton blanket
Number of subjects: 40
Study 363347 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdermal implants of levonorgestrel
Number of subjects: 0
Study 363347 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdermal implants of norgestrel
Number of subjects: 0
Study 363347 — intervention group
Group type: COMPARATOR
Intervention: Copper T200 (control)
Number of subjects: 0
Study 363347 — intervention group
Group type: EXPERIMENTAL
Intervention: Termination of use
Number of subjects: 0
Study 28125158 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO)
Number of subjects: 20
Study 28125158 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 26100581 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual family meetings (conference calling or Skype videoconferencing)
Number of subjects: 88
Study 26100581 — intervention group
Group type: COMPARATOR
Intervention: Control meetings (traditional family meetings)
Number of subjects: 88
Study 26100581 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual family meetings
Number of subjects: 88
Study 26100581 — intervention group
Group type: COMPARATOR
Intervention: Control meetings
Number of subjects: 88
Study 24415390 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant feeding intervention
Number of subjects: 698
Study 22046961 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD/FORM 160/4.5 μg, two inhalations twice daily
Number of subjects: 308
Study 22046961 — intervention group
Group type: COMPARATOR
Intervention: BUD 200 μg, two inhalations twice daily
Number of subjects: 308
Study 20011770 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-free, adhesively luted composite crowns (Artglass, Heraeus Kulzer)
Number of subjects: 114
Study 17381400 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized ceftazidime
Number of subjects: 105
Study 17381400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 15347715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 20 mg/kg every 12 hours for 48-72 hours
Number of subjects: 51
Study 15347715 — intervention group
Group type: COMPARATOR
Intervention: Hepatobiliary scintigraphy without UDCA
Number of subjects: 51
Study 15347715 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatobiliary scintigraphy after UDCA treatment
Number of subjects: 51
Study 15347715 — intervention group
Group type: COMPARATOR
Intervention: Hepatobiliary scintigraphy
Number of subjects: 51
Study 11152850 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose simvastatin
Number of subjects: 20
Study 9539282 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous daily oral equine conjugated estrogen 0.625 mg (group A, N=10)
Number of subjects: 19
Study 9539282 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily transdermal 17beta‐estradiol 50 microg (group B, N=9)
Number of subjects: 19
Study 8088918 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 24
Study 8088918 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 24
Study 8088918 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (1 to 30 micrograms/min)
Number of subjects: 24
Study 2263919 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound (1:9, 0.5 watt/cm2 at 1 MHz, for 10 min) 3 days a week for 4 weeks, then twice weekly for 4 weeks, and once weekly for the following 4 weeks.
Number of subjects: 44
Study 2263919 — intervention group
Group type: COMPARATOR
Intervention: Placebo-ultrasound (standard treatment with paste impregnated bandage and self-adhesive elastic bandage).
Number of subjects: 44
Study 318825 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone phenpropionate
Number of subjects: 21
Study 318825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31083844 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive lecture
Number of subjects: 29
Study 31083844 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture
Number of subjects: 29
Study 27826653 — intervention group
Group type: EXPERIMENTAL
Intervention: F_1 (Lactobacillus acidophilus and Lactobacillus reuteri)
Number of subjects: 60
Study 27826653 — intervention group
Group type: EXPERIMENTAL
Intervention: F_2 (Lactobacillus plantarum, Lactobacillus rhamnosus and Bifidobacterium animalis subsp. lactis)
Number of subjects: 60
Study 27826653 — intervention group
Group type: COMPARATOR
Intervention: Placebo (F_3)
Number of subjects: 60
Study 25982297 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI with panitumumab
Number of subjects: 182
Study 25982297 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI with bevacizumab
Number of subjects: 182
Study 23497350 — intervention group
Group type: EXPERIMENTAL
Intervention: medical nutrition therapy + advice to consume at least two pieces of fruit a day (high‐fruit)
Number of subjects: 63
Study 23497350 — intervention group
Group type: COMPARATOR
Intervention: medical nutrition therapy + advice to consume no more than two pieces of fruit a day (low‐fruit)
Number of subjects: 63
Study 21775131 — intervention group
Group type: EXPERIMENTAL
Intervention: SAG (Stop and Go) strategy
Number of subjects: 42
Study 21775131 — intervention group
Group type: COMPARATOR
Intervention: 3DS (3 Days Switching) strategy
Number of subjects: 42
Study 19635971 — intervention group
Group type: EXPERIMENTAL
Intervention: T-wave inversion through V(3) in ARVD patients without complete RBBB or incomplete RBBB
Number of subjects: 100
Study 19635971 — intervention group
Group type: EXPERIMENTAL
Intervention: T-wave inversion through V(3) in ARVD patients with incomplete RBBB
Number of subjects: 100
Study 19635971 — intervention group
Group type: EXPERIMENTAL
Intervention: T-wave inversion through V(4) in ARVD patients with complete RBBB
Number of subjects: 100
Study 19635971 — intervention group
Group type: EXPERIMENTAL
Intervention: r'/s ratio in V(1) <1 in ARVD patients with complete RBBB
Number of subjects: 100
Study 19635971 — intervention group
Group type: EXPERIMENTAL
Intervention: r'/s ratio <1 in ARVD patients with complete RBBB
Number of subjects: 100
Study 16948990 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (1.5 g intravenous for 20 minutes)
Number of subjects: 24
Study 16948990 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous solution for 20 minutes)
Number of subjects: 24
Study 16586343 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer-specific intermittent exercise
Number of subjects: 8
Study 16586343 — intervention group
Group type: COMPARATOR
Intervention: Continuous exercise
Number of subjects: 8
Study 16586343 — intervention group
Group type: EXPERIMENTAL
Intervention: Both exercise types
Number of subjects: 8
Study 14613735 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day) for 3 months
Number of subjects: 40
Study 14613735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10586340 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg once daily orally (n = 29)
Number of subjects: 60
Study 10586340 — intervention group
Group type: COMPARATOR
Intervention: Formestane 250 mg once every two weeks by intramuscular injection (n = 31)
Number of subjects: 60
Study 10586340 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 60
Study 10586340 — intervention group
Group type: COMPARATOR
Intervention: Formestane
Number of subjects: 60
Study 10586340 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole and Formestane
Number of subjects: 60
Study 8757378 — intervention group
Group type: COMPARATOR
Intervention: Hepatic vascular exclusion (HVE)
Number of subjects: 52
Study 8757378 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal triad clamping (PTC)
Number of subjects: 52
Study 1657128 — intervention group
Group type: EXPERIMENTAL
Intervention: Single infusion of MAb C23 (5 to 80 mg)
Number of subjects: 20
Study 1657128 — intervention group
Group type: EXPERIMENTAL
Intervention: Three infusions of MAb C23 (60, 20, and 20 mg at 1-week intervals)
Number of subjects: 20
Study 1657128 — intervention group
Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 20
Study 6961425 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine (vitamin B-6) treatment
Number of subjects: 0
Study 6961425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30442217 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychological treatment program (8 one-hour sessions, cognitive-behavioral approach)
Number of subjects: 51
Study 27122490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine infusion of 500 IU hCG (n=7)
Number of subjects: 15
Study 27122490 — intervention group
Group type: COMPARATOR
Intervention: Embryo culture media vehicle (n=8)
Number of subjects: 15
Study 26059781 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (50 U per axilla)
Number of subjects: 141
Study 24036742 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 28
Study 24036742 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide associated with oxygen
Number of subjects: 28
Study 20372671 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief individual motivational interview
Number of subjects: 301
Study 20372671 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted school lecture
Number of subjects: 301
Study 20372671 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 301
Study 18462269 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV), frequency: 26 Hz, duration: 10 sets of 60 seconds with 60 seconds rest
Number of subjects: 10
Study 18462269 — intervention group
Group type: COMPARATOR
Intervention: Control (CON), no WBV stimulation
Number of subjects: 10
Study 16806871 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 acid ethyl esters at 62.5% concentration
Number of subjects: 101
Study 16806871 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 acid ethyl esters at 80% concentration
Number of subjects: 101
Study 16806871 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 acid ethyl esters at 85% concentration
Number of subjects: 101
Study 14533656 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom days
Number of subjects: 638
Study 14533656 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of predicted FEV1
Number of subjects: 638
Study 14533656 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma severity, use of peak expiratory flow rate meters, younger age, low-income status, nonwhite race, longer duration of asthma
Number of subjects: 638
Study 14533656 — intervention group
Group type: EXPERIMENTAL
Intervention: Total annual asthma-related cost
Number of subjects: 638
Study 14533656 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicines
Number of subjects: 638
Study 10835439 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 40000
Study 9355594 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 87
Study 9355594 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline
Number of subjects: 87
Study 8225149 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine (0.2-0.4 mg daily)
Number of subjects: 50
Study 8225149 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25-50 mg daily)
Number of subjects: 50
Study 8225149 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 50
Study 8225149 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 50
Study 3517926 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanozolol 5 mg twice daily for six months
Number of subjects: 40
Study 3517926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30348178 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (5 mg.kg-1)
Number of subjects: 12
Study 30348178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30348178 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion
Number of subjects: 12
Study 27996026 — intervention group
Group type: EXPERIMENTAL
Intervention: Public reporting of prescriptions
Number of subjects: 20
Study 25509236 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g intravenous (IV) paracetamol 20 min before the operation
Number of subjects: 60
Study 25509236 — intervention group
Group type: COMPARATOR
Intervention: 1 cc normal saline (placebo) 20 min before the operation
Number of subjects: 60
Study 22938071 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture Exchange Communication System (PECS)
Number of subjects: 18
Study 22938071 — intervention group
Group type: COMPARATOR
Intervention: Conventional Language Therapy (CLT)
Number of subjects: 18
Study 20712134 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of betahistine (16 mg tablet)
Number of subjects: 0
Study 20712134 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of betahistine (16 mg tablet)
Number of subjects: 0
Study 18230389 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol 0.05% ointment
Number of subjects: 30
Study 18230389 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 30
Study 15702296 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated delineation of a plan optimization volume (POV) and an irradiated volume (IV) using a computer algorithm with constrained matrix inversion (CMI) as optimization method.
Number of subjects: 0
Study 15702296 — intervention group
Group type: EXPERIMENTAL
Intervention: Human heuristics using only the central slice (2-D) for optimization.
Number of subjects: 0
Study 15702296 — intervention group
Group type: EXPERIMENTAL
Intervention: Human heuristics using the whole set of CT slices (3-D) for optimization.
Number of subjects: 0
Study 15702296 — intervention group
Group type: COMPARATOR
Intervention: Standard planning procedure at Ghent University Hospital, Belgium.
Number of subjects: 0
Study 12812866 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin levels of 35 microU/ml
Number of subjects: 37
Study 12812866 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin levels of 85 microU/ml
Number of subjects: 37
Study 12812866 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin levels of 25 microU/ml
Number of subjects: 37
Study 10827410 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 x 10(6) IU/m(2) of rIFN‐gamma (low‐dose group)
Number of subjects: 51
Study 10827410 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 x 10(6) IU/m(2) of rIFN‐gamma (high‐dose group)
Number of subjects: 51
Study 10827410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 10827410 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN‐gamma therapy (both dosages)
Number of subjects: 51
Study 10163997 — intervention group
Group type: EXPERIMENTAL
Intervention: Utility-based health status measures
Number of subjects: 0
Study 10163997 — intervention group
Group type: EXPERIMENTAL
Intervention: Other forms of health status measures
Number of subjects: 0
Study 1655353 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 138
Study 1655353 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonachlazine
Number of subjects: 138
Study 6409006 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432
Number of subjects: 53
Study 6409006 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 53
Study 30975111 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and physical fitness-related program (IG-run)
Number of subjects: 48
Study 30975111 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and physical fitness-related program (IG-game play)
Number of subjects: 48
Study 30975111 — intervention group
Group type: COMPARATOR
Intervention: Regular physical education lessons (CG-run)
Number of subjects: 48
Study 30975111 — intervention group
Group type: COMPARATOR
Intervention: Regular physical education lessons (CG-game play)
Number of subjects: 48
Study 30397721 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA-based prostate cancer screening (European Randomized Study for Screening of Prostate Cancer - ERSPC)
Number of subjects: 60000
Study 30397721 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-adapted screening intervals based on baseline PSA level assessment at a young age (40-50)
Number of subjects: 60000
Study 30397721 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-adapted prostate cancer screening (PROBASE study)
Number of subjects: 60000
Study 25965997 — intervention group
Group type: EXPERIMENTAL
Intervention: Humorous demonstration group
Number of subjects: 53
Study 25965997 — intervention group
Group type: COMPARATOR
Intervention: Control demonstration group
Number of subjects: 53
Study 24656715 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip strength measurements and trunk endurance assessment
Number of subjects: 38
Study 24656715 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk side‐plank endurance
Number of subjects: 38
Study 24656715 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric strength measurements
Number of subjects: 38
Study 22205315 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrée portion sizes of 100, 160, 220, 280, 340, and 400 g
Number of subjects: 17
Study 19439363 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 14911
Study 19439363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14911
Study 19439363 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all indications)
Number of subjects: 14911
Study 19439363 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine in MDD
Number of subjects: 14911
Study 18598831 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfurous‐arsenical‐ferruginous thermal water nasal irrigation
Number of subjects: 80
Study 18598831 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution nasal irrigation
Number of subjects: 80
Study 18598831 — intervention group
Group type: EXPERIMENTAL
Intervention: Both irrigation modalities
Number of subjects: 80
Study 15888638 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigator (PN+)
Number of subjects: 0
Study 15888638 — intervention group
Group type: COMPARATOR
Intervention: No Patient Navigator (PN-)
Number of subjects: 0
Study 11924590 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate 0.12% with 11% ethanol (group 1; CHX‐A)
Number of subjects: 96
Study 11924590 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate 0.12% without alcohol (group 2; CHX‐NA)
Number of subjects: 96
Study 11924590 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 3; P)
Number of subjects: 96
Study 10656954 — intervention group
Group type: EXPERIMENTAL
Intervention: Open cholecystectomy (group A)
Number of subjects: 20
Study 10656954 — intervention group
Group type: COMPARATOR
Intervention: Videolaparoscopic cholecystectomy (group B)
Number of subjects: 20
Study 8862298 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-matched defects in the upper plus middle zones
Number of subjects: 0
Study 8862298 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-matched defects in the lower zones
Number of subjects: 0
Study 8862298 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-matched defects involving 25-50% of a zone
Number of subjects: 0
Study 8862298 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller or larger triple-matched defects
Number of subjects: 0
Study 1538447 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral polytetrafluoroethylene (Teflon)-coated latex catheter
Number of subjects: 344
Study 1538447 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral polyvinylchloride catheter
Number of subjects: 344
Study 1538447 — intervention group
Group type: COMPARATOR
Intervention: Suprapubic polyvinylchloride catheter
Number of subjects: 344
Study 1538447 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 344
Study 1538447 — intervention group
Group type: COMPARATOR
Intervention: Suprapubic drainage group
Number of subjects: 344
Study 6238829 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin 10 mg
Number of subjects: 13
Study 6238829 — intervention group
Group type: EXPERIMENTAL
Intervention: amitriptyline 10 mg
Number of subjects: 13
Study 6238829 — intervention group
Group type: EXPERIMENTAL
Intervention: amitriptyline 50 mg
Number of subjects: 13
Study 6238829 — intervention group
Group type: EXPERIMENTAL
Intervention: zimeldine 200 mg
Number of subjects: 13
Study 6238829 — intervention group
Group type: EXPERIMENTAL
Intervention: ethanol 1 g/kg bodyweight
Number of subjects: 13
Study 6238829 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13
Study 29220609 — intervention group
Group type: EXPERIMENTAL
Intervention: SSF‐Assessment Group Therapy
Number of subjects: 141
Study 29220609 — intervention group
Group type: COMPARATOR
Intervention: Usual Assessment Group Therapy
Number of subjects: 141
Study 29516964 — intervention group
Group type: EXPERIMENTAL
Intervention: Rendezvous therapy (radiotherapy with local delivery of nimustine and oral temozolomide)
Number of subjects: 71
Study 29516964 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (radiotherapy with concomitant and adjuvant temozolomide)
Number of subjects: 71
Study 27397608 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention group (n = 677 boys)
Number of subjects: 1700
Study 27397608 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed intervention group (n = 658 girls)
Number of subjects: 1700
Study 27397608 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention group (n = 613 girls)
Number of subjects: 1700
Study 27397608 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed intervention group (n = 687 boys)
Number of subjects: 1700
Study 24647023 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (10-day course, oral)
Number of subjects: 96
Study 24647023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 24647023 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 96